SMARCA4/BRG1-deficient non-small cell lung cancer: clinical, imaging, pathological features, and follow-up results of 23 patients

作者：Xieraili Wumener, Xiaoxing Ye, Yarong Zhang, E Tuya, Jiuhui Zhao, Ying Liang, Jun Zhao · 发表于：Translational Lung Cancer Research · 年份：2025 · DOI：10.21037/tlcr-24-567 · 被引用次数：8 · 研究领域：Chromatin Remodeling and Cancer、Mechanisms of cancer metastasis、Cancer Mechanisms and Therapy

Background: SMARCA4/BRG1-deficient non-small cell lung cancer (S/B-d NSCLC) is a rare subtype of non-small cell lung cancer (NSCLC). The aim of this study was to investigate the clinical, imaging, serum tumor marker, and pathological features of S/B-d NSCLC, particularly computed tomography (CT) and 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) scan features. Methods: Our analysis included 23 patients with pathologically confirmed S/B-d NSCLC from January 2021 to December 2023. A retrospective analysis of clinical, serum tumor markers, imaging [including CT, FDG PET/CT, magnetic resonance imaging (MRI)], pathological features, treatment protocols, and follow-up results was performed. Independent samples t-tests were used to assess statistical differences in short diameters and maximum standardized uptake value (SUVmax) between groups. Results: S/B-d NSCLC occurs predominantly in male patients with a history of smoking and a mean age of 62.78 years (39–77 years). S/B-d NSCLC was found incidentally during physical examination in 56.52% of patients. The CT scan features were as follows: predominantly tumors (72.73%), peripheral in the lungs (77.27%), round or roundish morphology (81.28%), pleural or vascular invasion (95.46%), and moderately to severely enhanced (59.09%). The FDG PET/CT showed FDG-avid with mean SUVmax of 14.78±9.57. Lung cancer-related serum tumor markers had high positivity rates for carcinoembryonic antigen (CEA) (66.6...